Last reviewed · How we verify
Symbicort Turbohaler without Turbo+
Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.
Symbicort combines an inhaled corticosteroid (budesonide) and a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Symbicort Turbohaler without Turbo+ |
|---|---|
| Sponsor | Istituto per la Ricerca e l'Innovazione Biomedica |
| Drug class | Inhaled corticosteroid/long-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor; beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Budesonide acts as a potent anti-inflammatory corticosteroid that suppresses airway inflammation and mucus production. Formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, improving airflow. Together, they provide both anti-inflammatory and bronchodilator effects for sustained asthma and COPD control.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Nervousness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: